In Brief: Hi-Tech Pharmacal, OTC firm warned on water tests, John Taylor to leave FDA, NAD and ASA review claims
This article was originally published in The Tan Sheet
Executive Summary
Hi-Tech Pharmacal profits plummet; FDA warns OTC firm about GMPs; John Taylor to leave FDA; NAD refers claims for Vysera-CLS to FTC; Circulation Patch It claims lack support – ASA; and U.K. liquid OTC recalls.
You may also be interested in...
Class Action Continues Against Zantrex-3 Maker After Rejected Settlement
The ruling in US District Court for the Eastern New York District notes a Supreme Court decision in January in a separate case that also focused on settlement offers rejected by plaintiffs in civil litigation, a question on which US appellate courts have differed.
Hi-Tech Deal Broadens Akorn Consumer Business
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: